Medical Hypotheses
Volume 55, Issue 6 , Pages 485-490 , December 2000

Lessons from pregnancy and parturition: uterine leiomyomas result from discordant differentiation and dedifferentiation responses in smooth muscle cells

  • K. Cesen-Cummings

      Affiliations

    • National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
    • ,
  • C.L. Walker

      Affiliations

    • National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
    • Science Park Research Division, University of Texas M.D. Anderson Cancer Center, Smithville, Texas, USA
    • ,
  • B.J. Davis

      Affiliations

    • National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA

Received 2 November 1999 ,Accepted 16 February 2000.

References 

    REFERENCES
  1. Brett K, Marsh J, Madans J. Epidemiology of hysterectomy in the United States: demographic and reproductive factors in a nationally representative sample. Journal of Women’s Health. 1997;6:309–316
  2. Wilcox L, Koonin L, Pokras R, Strauss L, Xia Z, Peterson H. Hysterectomy in the United States, 1988–1990. Obstet Gynecol. 1994;83:549–555
  3. Baird D, Schectman J, Dixon D, Sandler D, Hill M. African Americans at higher risk than whites for uterine fibroids: ultrasound evidence. Am J Epidemiol. 1998;147:358
  4. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogake H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol. 1989;160:637–641
  5. Buttram V, Reiter R. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981;36:433–445
  6. Marshall LM, Spiegelman D, Barbieri RL. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90:967–973
  7. Parazzini F, La Vecchia C, Negri E, Cecchetti G, Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol. 1988;72:853–857
  8. Ross R, Pike M, Vessey M, Bull D, Yeates D, Casagrandy J. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ. 1986;293:359–362
  9. Sato F, Nishi M, Kudo R, Miyake H. Body fat distribution and uterine leiomyomas. J Epidemiol. 1998;8:176–180
  10. Filicori M, Hall D, Loughlin J, Rivier J, Vale W, Crowley W. A conservative approach to the management of uterine leiomyoma. Pituitary desensitization by a luteinizing hormone releasing hormone analogue. Am J Obstet Gynecol. 1983;147:726–727
  11. Friedman A, Daly M, Juneau-Norcorss M, Rein M. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Fertil Steril. 1992;58:413–415
  12. Pandis N, Heim S, Bardi G. Chromosome analysis of 96 uterine leiomyomas. Cancer Genet Cytogenet. 1991;55:11–18
  13. Packenham J, du Manoir S, Schrock E. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. Mol Carcinog. 1997;19:273–279
  14. Zeng W, Scherer S, Koutsilieris M. Loss of heterozygosity and reduced expression of the CUTLI gene in uterine leiomyomas. Oncogene. 1997;14:2355–2365
  15. Ishwad CS, Ferrell RE, Hanley K. Two discrete regions of deletion at 7q in uterine leiomyomas. Genes Chromosom Cancer. 1997;19:156–160
  16. Vanni R, Marras S, Schoenmakers EFPM. Molecular cytogenetic characterization of del(7q) in two uterine leiomyoma-derived cell lines. Genes Chromosom Cancer. 1997;18:155–161
  17. Morton C. Many tumors and many genes: genetics of uterine leiomyomata. Am J Pathol. 1998;153:1015–1020
  18. Bustin M, Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol. 1996;54:35–100
  19. Williams AJ, Powell WL, Collins T, Morton CC. HMGI(Y) expression in human uterine leiomyomata. Involvement of another high-mobility group architectural factor in a benign neoplasm [see comments]. Am J Pathol. 1997;150:911–918
  20. Andersen J, Barbieri RL. Abnormal gene expression in uterine leiomyomas. J Soc Gynecol Investig. 1995;2:663–672
  21. Risek B, Guthrie S, Kumar N, Gilula N. Modulation of gap junction transcript and protein expression during pregnancy in the rat. J Cell Biol. 1990;110:269–282
  22. Garfield R, Sims S, Daniel E. Gap junctions: their presence and necessity in myometrium during parturition. Science. 1977;198:958–960
  23. Andersen J, Grine E, Eng C. Expression of connexin-43 in human myometrium and leiomyoma. Am J Obstet Gynecol. 1993;169:1266–1276
  24. Hendrix E, Myatt L, Sellers S, Russell P, Larsen W. Steroid hormone regulation of rat myometrial gap junction formation: effects on cx43 levels and trafficking. Biol Reprod. 1995;52:547–560
  25. Yu W, Dahl G, Werner R. The connexin43 gene is responsive to oestrogen. Proc R Soc Lond B Biol Sci. 1994;255:125–132
  26. Zhao K, Kuperman L, Geimonen E, Andersen J. Progestin represses human connexin43 gene expression similarly in primary cultures of myometrial and uterine leiomyoma cells. Biol Reprod. 1996;54:607–615
  27. Tiltman AJ. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol. 1985;4:89–96
  28. Kawaguchi K, Fujii S, Konishi I. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch A Pathol Anat Histopathol. 1991;419:309–315
  29. Lessey BA, Killam AP, Metzger DA, Haney AF, Green GL, McCarty KS. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab. 1988;67:334–340
  30. How H, Huang Z-H, Zuo J, Lei Z, Spinnato J, Rao C. Myometrial estradiol and progesterone receptor changes in preterm and term pregnancies. Obstet Gynecol. 1995;86:936–940
  31. Brandon DD, Bethea CL, Strawn EY. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol. 1993;169:78–85
  32. Soules MR, McCarty KS. Leiomyomas: steroid receptor content. Variation within normal menstrual cycles. Am J Obstet Gynecol. 1982;143:6–11
  33. Lessl M, Klotzbuecher M, Schoen S, Reles A, Stockemann K, Fuhrmann U. Comparative messenger ribonucleic acid analysis of immediate early genes and sex steroid receptors in human leiomyoma and healthy myometrium. J Clin Endocrinol Metab. 1997;82:2596–2600
  34. Vollenhoven BJ, Pearce P, Herington AC, Healy DL. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women. Clin Endocrinol (Oxf). 1994;40:537–544
  35. Fujimoto J, Hirose R, Ichigo S, Sakaguchi H, Li Y, Tamaya T. Expression of progesterone receptor form A and B mRNAs in uterine leiomyoma. Tumor Biol. 1998;19:126–131
  36. Snijders M, de Goeij A, Debets-Te Baerts M, Rousch M, Koudstaal J, Bosman F. Immunoctyochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause. J Reprod Fert. 1992;94:363–371
  37. Pedeutour F, Quade BJ, Weremowicz S, Dal Cin P, Ali S, Morton CC. Localization and expression of the human estrogen receptor beta gene in uterine leiomyomata. Genes Chromosom Cancer. 1998;23:361–366
  38. Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol. 1980;55:20–24
  39. Rein M, Nowak R. Biology of uterine myomas and myometrium in vitro. Semin Reprod Endocrinol. 1992;10:310–319
  40. Englund K, Blanck A, Gustavsson I. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab. 1998;83:4092–4096
  41. Carsten M. Regulation of myometrial composition, growth, and activity. In:  Assali N editors. Biology of gestation I, the maternal organism. New York: Academic Press,; 1968;
  42. Palmer SS, Haynes-Johnson D, Diehl T, Nowak RA. Increased expression of stromelysin 3 mRNA in leiomyomas (uterine fibroids) compared with myometrium. J Soc Gynecol Investig. 1998;5:203–209
  43. Wolanska M, Sobolewski K, Drozdzewicz M, Bankowski E. Extracellular matrix components in uterine leiomyoma and their alteration during the tumour growth. Mol Cell Biochem. 1998;189:145–152
  44. Boettger-Tong H, Shipley G, Hsu C-J, Stancel GM. Cultured human uterine smooth muscle cells are retinoid responsive. PSEBM. 1997;215:59–65
  45. Corbeil J, Rapaport E, Richman D, Loonly D. Antiproliferative effect of retinoid compounds on kaposi’s sarcoma cells. J Clin Invest. 1994;93:1981–1986
  46. Boehm N, Chateau D, Rochette-Elgy C. Retinoid receptors in rat vaginal and uterine epithelia: changes with ovarian steroids. Molec Cell Endocrin. 1997;132:101–108
  47. Gearing K, Gottlicher M, Teboul M, Widmark E, Gustafsson J. Interaction of the peroxisome proliferator-activated receptor and retinoid x receptor. Proc Natl Acad Sci USA. 1993;90:1440–1444
  48. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature. 1992;358:771–774
  49. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803–812
  50. Kliewer SA, Sundseth SS, Jones SA. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA. 1997;94:4318–4323
  51. Mandrup S, Lane M. Regulating adipogenesis. J Biol Chem. 1997;272:5367–5370
  52. Iijima K, Yoshizumi M, Ako J. Expression of peroxisome proliferator-activated receptor (PPAR) in rat aortic smooth muscle cells. Biochem Biophys Res Comm. 1998;247:353–356
  53. Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol. 1995;9:794–804
  54. Nunez S, Medin J, Braissant O. Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol Cell Endocrinol. 1997;127:27–40
  55. Ma H, Sprecher H, Kolattukudy P. Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARgamma-expressing tissue. J Bio Chem. 1998;273:30131–30138
  56. Hino O, Klein-Szanto A, Freed J. Spontaneous and radiation-induced renal tumors in the Eker rat model of dominantly inherited cancer. Proc Natl Acad Sci USA. 1993;90:327–331
  57. Yeung R, Xiao G, Jin F, Lee W, Testa J, Knudson A. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci USA. 1994;91:11413–11416
  58. Henry K, Yuan X, Koszewski N, Onda H, Kwiatkowski D, Noonan D. Tuberous sclerosis gene 2 product modulates transcription mediated by steriod hormone receptor family members. J Biol Chem. 1998;273:20535–20539
  59. Mizutani T, Sugihara A, Nakamuro K, Terada N. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin Endocrinol Metab. 1998;83:1253–1255
  60. Matsuo H, Maruo T, Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab. 1997;82:293–299
  61. Burroughs KD, Kiguchi K, Howe SR. Regulation of apoptosis in uterine leiomyomata [published erratum appears in Endocrinology 1997 Sep; 138(9): 3786]. Endocrinology. 1997;138:3056–3064
  62. Geyer H, de Gregorio G, Lernbecher G. Oestrogen and progesterone receptors in the involuting rat uterus. Acta Endocrinol. 1982;100:450–454
  63. Brodt-Eppley J, Myatt L. Changes in expression of contractile FP and relaxatory EP2 receptors in pregnant rat myometrium during late gestation, at labor, and postpartum. Biol Reprod. 1998;59:878–883
  64. Broderick R, Broderick K. Ultrastructure and Calcium Stores in the Myometrium. In:  Carsten M,  Miller J editor. Uterine Function: Molecular and Cellular Aspects. New York: Plenum Press; 1990;p. 1–34
  65. Woessner JF. Regulation of matrilysin in the rat uterus. Biochem Cell Biol. 1996;74:777–784
  66. Balbin M, Fueyo A, Knauper V. Collagenase 2 (MMP-8) expression in murine tissue-remodeling processes. Analysis of its potential role in postpartum involution of the uterus. J Biol Chem. 1998;273:23959–23968
  67. Rudolph-Owen LA, Hulboy DL, Wilson CL, Mudgett J, Matrisian LM. Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology. 1997;138:4902–4911
  68. Blair HC, Teitelbaum SL, Ehlich LS, Jeffrey JJ. Collagenase production by smooth muscle: correlation of immunoreactive with functional enzyme in the myometrium. J Cell Physiol. 1986;129:111–123

PII: S0306-9877(00)91098-3

doi: 10.1054/mehy.2000.1098

Medical Hypotheses
Volume 55, Issue 6 , Pages 485-490 , December 2000

Article Tools